Donanemab in Early Alzheimer’s Disease

A phase 2 trial of donanemab, an antibody that targets amyloid deposited in the brain, showed a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks in patients with early Alzheimer’s disease. Results for secondary outcomes were gene...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 384; no. 18; pp. 1691 - 1704
Main Authors Mintun, Mark A, Lo, Albert C, Duggan Evans, Cynthia, Wessels, Alette M, Ardayfio, Paul A, Andersen, Scott W, Shcherbinin, Sergey, Sparks, JonDavid, Sims, John R, Brys, Miroslaw, Apostolova, Liana G, Salloway, Stephen P, Skovronsky, Daniel M
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 06.05.2021
Subjects
Activities of Daily Living
Administration, Intravenous
Aged
Alzheimer Disease - drug therapy
Alzheimer's disease
Brain Edema - chemically induced
Clinical trials
Cognition - drug effects
Cognitive ability
Dementia
Dementia disorders
Disease Progression
Double-Blind Method
Edema
Epitopes
Female
Humans
International organizations
Magnetic resonance imaging
Male
Mental Status and Dementia Tests
Neurodegenerative diseases
Patients
Placebos
Plaque, Amyloid - drug therapy
Positron emission tomography
Pyrrolidonecarboxylic Acid - antagonists & inhibitors
Severity of Illness Index
Tau protein
β-Amyloid
Online AccessGet full text

Cover

More Information
Summary:A phase 2 trial of donanemab, an antibody that targets amyloid deposited in the brain, showed a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks in patients with early Alzheimer’s disease. Results for secondary outcomes were generally similar in the two trial groups.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2100708